Jeffrey A. Meckler
CEO and Director at Indaptus Therapeutics Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Indaptus Therapeutics Inc., 3 years.
Indaptus Therapeutics Inc.
Director · Co-Chief Executive Officer
Travere Therapeutics Inc.
Director
Chief executive roles
Indaptus Therapeutics Inc.
· CEO and Director
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 19, 2026 | Travere Therapeutics Inc. | Grant or award | +4,000 | — | — |
| May 4, 2026 | Travere Therapeutics Inc. | Option exercise | +8,000 | $16.33 | $130,640 |
| May 4, 2026 | Travere Therapeutics Inc. | Open-market sale | −8,000 | $45.00 | $360,000 |
| Dec 22, 2025 | Indaptus Therapeutics Inc. | Grant or award | +216,617 | $2.03 | $439,733 |
| Jul 27, 2025 | Indaptus Therapeutics Inc. | Grant or award | +6,068 | $8.30 | $50,364 |
| May 15, 2025 | Travere Therapeutics Inc. | Grant or award | +6,500 | — | — |
| Nov 25, 2024 | Indaptus Therapeutics Inc. | Grant or award | +42,553 | $1.18 | $50,213 |
| Sep 30, 2024 | Travere Therapeutics Inc. | Option exercise | +40,000 | $10.48 | $419,200 |
| Sep 30, 2024 | Travere Therapeutics Inc. | Open-market sale | −40,000 | $14.06 | $562,400 |
| Aug 8, 2024 | Indaptus Therapeutics Inc. | Grant or award | +84,932 | $1.83 | $155,426 |
| May 8, 2024 | Travere Therapeutics Inc. | Grant or award | +6,500 | — | — |
| May 17, 2023 | Travere Therapeutics Inc. | Grant or award | +4,500 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.